The European Regulatory Environment of RNA-Based Vaccines (Q40405913)

20 September 2017

The European Regulatory Environment of RNA-Based Vaccines (English)

1 reference

20 September 2017

11

1 reference

20 September 2017

Ulrich Kalinke

14

0 references

Hans-Georg Rammensee

10

object named as

Hans-Georg Rammensee

1 reference

20 September 2017

13

Özlem Türeci

1 reference

20 September 2017

9

Sebastian Kreiter

1 reference

20 September 2017

7

Christoph Huber

1 reference

20 September 2017

3

Cedrik M Britten

1 reference

20 September 2017

4

Bruno Flamion

1 reference

20 September 2017

6

Axel Hoos

1 reference

20 September 2017

8

Samir Khleif

1 reference

20 September 2017

Harpreet Singh-Jasuja

12

object named as

Harpreet Singh-Jasuja

1 reference

20 September 2017

Thomas Hinz

1

1 reference

20 September 2017

Kajo Kallen

2

1 reference

20 September 2017

Ulrich Granzer

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 2017

1 reference

Methods in Molecular Biology

20 September 2017

1 reference

20 September 2017

1499

1 reference

20 September 2017

203-222

1 reference

Characteristics and stabilization of DNAase-sensitive protein synthesis in E. coli extracts

20 September 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Genetic immunization is a simple method for eliciting an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

In vitro transcription of long RNA containing modified nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Developing mRNA-vaccine technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

mRNA-based therapeutics--developing a new class of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

The regulatory landscape for actively personalized cancer immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Exploiting the mutanome for tumor vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Mutated tumor alleles are expressed according to their DNA frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Nonviral delivery of self-amplifying RNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Vaccines 'on demand': science fiction or a future reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

RNA: the new revolution in nucleic acid vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6481-9_13

10.1007/978-1-4939-6481-9_13

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference